I-Mab Management to Discuss Innovative Cancer Treatments Soon
I-Mab Management to Discuss Innovative Cancer Treatments Soon
ROCKVILLE, Md. — I-Mab (NASDAQ: IMAB), a global biotech leader, is dedicated to developing advanced immuno-oncology therapies that target cancer. The company recently announced its participation in the H.C. Wainwright "HCW@Home" Series, scheduled for a virtual format, showcasing vital advancements in cancer treatments.
Overview of Presentation and Upcoming Release
The focal point of the presentation will be the Claudin 18.2 landscape, a recognized therapeutic target in treating gastric cancers. In particular, the discussion will revolve around givastomig, proposed as a premier bispecific antibody targeting Claudin 18.2 and 4-1BB. This innovative antibody is currently under development for Claudin 18.2-positive gastric cancers, a significant area of research within oncological therapeutics.
Phase 1 Study and Presentation Details
The Phase 1 dose escalation study evaluating givastomig alongside immunochemotherapy will be highlighted. This study is also recognized for a Mini Oral presentation at the upcoming ESMO GI Cancers Congress. This important conference will take place on July 2.
Event Details for Participation
Details for the H.C. Wainwright event are as follows:
H.C. Wainwright “HCW@Home with I-Mab”
Format: Fireside Chat
Moderator: Andres Maldonado, PhD, Senior Analyst, H.C. Wainwright
I-Mab Speakers:
- Sean Fu, PhD, MBA, Chief Executive Officer
- Phillip Dennis, MD, PhD, Chief Medical Officer
Date: Tuesday, June 17
Time: 10:00 AM to 11:00 AM ET
Webcast Registration: Register here
About I-Mab and Its Vision
I-Mab is a biopharmaceutical powerhouse focused on innovating immuno-oncology solutions aimed at treating various forms of cancer. The company’s leading candidate, givastomig, showcases its cutting-edge research approach, highlighting its role in activating T cells through the 4-1BB signaling pathway. This targeted therapy is primarily developed for first-line metastatic gastric cancers but shows promise for other solid tumor treatments as well.
Research and Development Insights
In preliminary Phase 1 trials, givastomig has demonstrated robust tumor-binding capabilities and significant anti-tumor effects, suggesting potential synergistic advantages with existing treatment regimens. These findings are essential as they indicate a shift towards more effective and less toxic oncology treatments, aligning with I-Mab's commitment to healthcare innovation.
Stay Updated with I-Mab
To stay informed about the latest advancements from I-Mab, visit www.i-mabbiopharma.com and follow I-Mab on social media platforms such as LinkedIn and X.
Frequently Asked Questions
What is I-Mab focusing on during the H.C. Wainwright event?
I-Mab will present their innovations regarding Claudin 18.2-targeted therapies, particularly the bispecific antibody, givastomig.
When is the H.C. Wainwright event scheduled?
The event will occur on June 17, and will feature a discussion from 10:00 AM to 11:00 AM ET.
Who are the speakers representing I-Mab?
The event will feature Sean Fu, the CEO, and Phillip Dennis, the Chief Medical Officer, among others.
What is givastomig?
Givastomig is a novel bispecific antibody developed by I-Mab, aimed at treating Claudin 18.2-positive gastric cancers.
How can I access the webcast of the event?
The webcast will be available on the I-Mab website’s News & Events page for 90 days following the talk.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.